IMCRC – Supporting medical innovation
From predicting the risk of heart problems, to building blood vessels outside of the body, to tackling bacterial biofilms, IMCRC is involved in a host of projects in support of groundbreaking medical innovations.
A hand-held device to predict heart failure based on saliva could help millions of potential victims take preventative steps to avoid their fate. Nano-sensors on the tip of the diagnostic stick measure heart disease biomarkers from saliva to accurately predict the risk of heart disease, failure or heart attack, then warn users via a simple app. Now a multi-partner deal has just been signed to bring the lifesaving technology to market by 2021.
The collaboration is being led by an Australian start-up based in Melbourne called ESN Cleer, with RMIT University and the IMCRC now researching and developing the device for pilot manufacture. ESN Cleer CEO Leopoldt de Bruin says the collaboration represents some of the best minds in medical device innovation, design and manufacture.
“We’re really pleased to be able to bring these strands together in addressing such a major global health challenge,” De Bruin said. “Of the 400 million people who suffer from cardiovascular disease globally, only 16% of cases are due to genetic traits. This underlines how much room there is to improve on screening and prevention, which is where this device could have such an impact.”
Building blood vessel implants
A project working on building blood vessels outside of the body has attracted further industry attention, with the IMCRC joining Dr Steven Wise and Codex Research in the research collaboration. Dr Steven Wise and his team in the Faculty of Medicine and Health at the University of Sydney (UoS) have partnered with the IMCRC, after securing backing from Codex Research earlier this year.
Dr Wise’s work aims to improve the treatment of heart disease by engineering a physiologically relevant blood vessel implant used in bypass surgery. To reduce the failure rate compared with traditional plastic counterparts, Dr Wise and his team employ a range of synthetic and natural materials with the aim of developing new synthetic graft materials which combine tailored mechanical properties with improved biocompatibility. Current lab-based methods to assess these new materials have significant limitations, and better mimicry of human systems in a laboratory environment would greatly benefit this research area.
As well as funding, IMCRC has provided substantial support and guidance in helping to focus on business and manufacturing requirements, and has helped to crystalise a sophisticated business model for the project.
Novel solutions for biofilm infections
In early August the first annual review meeting was conducted for the Novel Solutions for the Biofilm Infections research project. This is a collaborative research project between the IMCRC, UoS and Whiteley Corporation, with an investment of over $4m over four years.
“This work will be of major medical significance worldwide” says Dr Greg Whiteley, Executive Chairman at Whiteley Corporation. “Bacterial biofilms cause both human disease and death, and these microbes are also responsible for contamination in industrial and institutional settings.”
Since the project commenced in mid-2018, great progress has been made in both research and model development.
“A paper entitled ‘Conditions under which glutathione disrupts the biofilms and improves antibiotic efficacy of both ESKAPE and non-ESKAPE species’ was recently published in the high impact journal Frontiers in Microbiology,” says Dr Jim Manos of UoS. “The paper shows that the antioxidant glutathione (GSH) not only disrupts biofilm in a wide range of bacterial species, including Pseudomonas aeruginosa, but also enhances the effectiveness of antibiotics against these bacteria.”
A second area where much progress has been made is in the development of a range of models to better represent the various areas in which biofilms effect the human body. The project is on track to deliver its key milestones and inform the manufacturing processes and technologies required to commercialise, and has received a green light from IMCRC.